Zacks: Analysts Anticipate Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Will Announce Earnings of $3.75 Per Share

Equities analysts predict that Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) will post earnings per share (EPS) of $3.75 for the current quarter, according to Zacks. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $3.32 and the highest estimate coming in at $4.35. Jazz Pharmaceuticals posted earnings per share of $3.92 during the same quarter last year, which indicates a negative year over year growth rate of 4.3%. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $16.50 per share for the current financial year, with EPS estimates ranging from $16.08 to $17.31. For the next financial year, analysts expect that the business will post earnings of $18.04 per share, with EPS estimates ranging from $15.00 to $22.16. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last issued its earnings results on Tuesday, March 1st. The specialty pharmaceutical company reported $3.66 EPS for the quarter, beating the consensus estimate of $2.98 by $0.68. The business had revenue of $896.73 million for the quarter, compared to the consensus estimate of $866.71 million. Jazz Pharmaceuticals had a positive return on equity of 21.56% and a negative net margin of 10.65%. The company’s revenue was up 34.7% compared to the same quarter last year. During the same period last year, the business posted $3.56 EPS.

JAZZ has been the topic of a number of recent analyst reports. Truist Financial raised their price target on Jazz Pharmaceuticals from $180.00 to $200.00 in a report on Thursday, January 20th. BMO Capital Markets reduced their target price on Jazz Pharmaceuticals from $202.00 to $187.00 in a report on Wednesday, March 2nd. HC Wainwright lifted their price target on Jazz Pharmaceuticals from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Thursday, March 3rd. StockNews.com upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 2nd. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $203.40.

Shares of Jazz Pharmaceuticals stock opened at $160.16 on Friday. Jazz Pharmaceuticals has a one year low of $117.64 and a one year high of $189.00. The stock’s fifty day moving average is $150.71 and its 200 day moving average is $139.25. The stock has a market cap of $9.89 billion, a P/E ratio of -29.39, a P/E/G ratio of 1.43 and a beta of 0.87. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.90 and a current ratio of 3.23.

In other news, CEO Bruce C. Cozadd sold 6,372 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, February 1st. The shares were sold at an average price of $139.23, for a total transaction of $887,173.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 10,772 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $158.33, for a total transaction of $1,705,530.76. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Quent Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at $31,000. National Bank of Canada FI acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth about $35,000. CWM LLC acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $43,000. Itau Unibanco Holding S.A. raised its holdings in Jazz Pharmaceuticals by 62.8% in the 4th quarter. Itau Unibanco Holding S.A. now owns 609 shares of the specialty pharmaceutical company’s stock valued at $78,000 after acquiring an additional 235 shares during the last quarter. Finally, KRS Capital Management LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $104,000. 91.95% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Featured Articles

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.